The development of new antibiotics and the emergence of novel resistance mechanisms to counteract these drugs create a dynamic and challenging task for the clinical microbiology laboratory. The goal of antimicrobial resistance testing is to provide timely therapeutic options to guide the management of infectious diseases resulting from bacterial infections. Antimicrobial susceptibility has classically been determined using a variety of in vitro methods, such as disk diffusion, broth microdilution, and automated instrument-based methods. Using these methods, the reporting of MICs and interpretations can require 24 to 96 h after a pure culture of the suspected pathogen is obtained (6). Unfortunately, results obtained after 48 h are often of little clinical value and are unlikely to alter antimicrobial therapy. The extended turnaround associated with phenotypic antimicrobial resistance testing provides an opportunity for the use of alternative technologies capable of producing more timely results. The first reports in this supplement explore the manner in which the criteria for interpreting MICs are developed and the clinical relevance of antimicrobial susceptibility testing. In this report, we present an alternative to routine susceptibility testing and examine the role of molecular susceptibility testing now and in the future.
The demand for molecular susceptibility testing has never been greater. The need for clinically relevant results and decreased turnaround times continues to drive development of rapid susceptibility testing. Molecular susceptibility testing has the potential to be the most rapid and sensitive approach for detection of resistance determinants but has been plagued by impediments since its inception. While more than 10 years have elapsed since the first PCR assay for methicillin-resistant Staphylococcus aureus (MRSA) was approved by the United States Food and Drug Administration (FDA) (14) , relatively few additional assays have been considered. Among these are tests for vancomycin resistance determinants in Enterococcus spp. (12) and tests for rifampin resistance in Mycobacterium tuberculosis (2, 4) .
The utility of molecular susceptibility tests is dependent on detecting all common drug resistance mechanisms. For example, the mechanism mediating methicillin resistance in S. aureus can easily be detected by using either the mecA gene or the staphylococcal cassette chromosome mec (SCCmec)-orfX junction as a marker (7, 14) . While the mecA gene is central for identification of methicillin resistance in Staphylococcus, it is not specific to MRSA. Additionally, mecA-based detection assays will also be positive for methicillin-resistant coagulasenegative Staphylococcus (CoNS). In contrast, assays that detect the SCCmec-orfX junction do not directly detect the functional determinant of methicillin resistance, mecA, but instead use proper integration of the SCCmec cassette proximal to orfX as a surrogate marker. The benefit of using the SCCmec-orfX junction as a molecular target is that when it is properly integrated, a single orfX-specific primer along with primers specific to each SCCmec type and a single probe spanning the orfXSCCmec junction will identify and confirm methicillin resistance in a single assay (9, 14) . Rarely, the use of the orfXSCCmec junction as a marker for methicillin resistance has resulted in false-positive genotypic tests (3) compared to the results of culture-based susceptibility tests. This is due to a recombination event within the mecA gene that results in an SCCmec-positive (methicillin-resistant) genotype while the strain remains phenotypically susceptible (3) .
Another challenge of molecular susceptibility testing is the characterization of mutations responsible for the resistance phenotype and the development of tests specific for these markers. With Mycobacterium tuberculosis, for instance, mutants generated during in vitro selection of antibiotic-resistant strains may differ substantially from those that naturally arise in human populations and cause clinical disease (11) . For this reason, it is essential to perform genotypic investigations with representative samples of clinical isolates. According to Piatek et al. (11) , "12 to 75% of isoniazid-resistant strains have been found to contain mutations either in codon 315 of the katG gene or the inhA ribosomal binding site, and an additional 13 to 18% have contained mutations in the ahpC-oxyR intergenic region, often in conjunction with katG mutations outside codon 315." In contrast, isoniazid-susceptible M. tuberculosis isolates have nearly uniformly wild-type DNA sequences in these regions (11) .
A third challenge to molecular susceptibility testing is the clinical specificity of the assay. Timely detection of vancomycin-resistant enterococci (VRE) is of significant clinical value for managing multidrug-resistant infections and ensuring that appropriate infection control measures are implemented (12) . Current PCR assays use the vancomycin resistance determinants vanA and vanB as surrogate markers for both vancomycin resistance and identification of Enterococcus faecium or Enterococcus faecalis. The problem with this scheme is that vanA and vanB are not unique to Enterococcus and the assays lack an additional marker specific to Enterococcus. Reports have described vanB to be carried by Streptococcus mitis, Streptococcus bovis, Eggerthella lenta, Clostridium spp., and Ruminococcus lactaris, and vanA has been associated with vancomycin-resistant S. aureus (8) . Carriage of vancomycin resistance determinants among many organisms, in addition to screening for VRE in stool specimens (which may contain PCR inhibitors and naked DNA from dead organisms), has led to several reports citing specificities of VRE PCRs as low as 75% and positive predictive values as low as 1.42% (8) . Development of assays with adequate clinical specificity must be a foremost consideration for future targets.
The largest need and greatest challenge in developing molecular assays to detect resistance determinants is among the Gram-negative bacilli. Among the members of the family Enterobacteriaceae, several hundred mechanisms have been reported to cause antimicrobial resistance, with most determinants causing resistance to beta-lactams, cephalosporins, monobactams, or carbapenems (13) . While genotypic determinants have been described for most resistance mechanisms, detection of each of these mechanisms requires special considerations, including whether to detect DNA or RNA, whether to utilize high-throughput multiplexing, how to distinguish between carriage and expression of resistance determinants, the need to identify subtle single nucleotide polymorphisms (SNPs), and the application of proteomics.
Beta-lactam resistance among Enterobacteriaceae can be attributed to several mechanisms, but the most important include the extended-spectrum beta-lactamases (ESBLs), AmpCs, metallo-beta-lactamases (MBLs), and Klebsiella pneumoniae carbapenemases (KPCs). More than 200 genotypically unique ESBLs have been described to date, with subtle genetic changes resulting in significant phenotypic differences. For example, TEM10 differs from TEM12 by a single amino acid (G240L); however, for strains carrying these enzymes, the MICs of ceftazidime differ by Ͼ10-fold and the MICs of aztreonam differ by Ͼ100-fold. Therefore, development of techniques that can detect individual SNPs will be critical for detection and classification of Gram-negative resistance (5) . Similarly, plasmid-borne genes encoding KPCs are highly expressed and lead to universal resistance to beta-lactam antibiotics, while the same KPCs encoded chromosomally may not be expressed and, as a result, may not confer resistance (10) . Thus, differentiating between plasmid carriage and chromosomal carriage of KPC genes will determine how antimicrobials should be reported. If a molecular screening test is used as the sole susceptibility testing method, it could result in an isolated organism being reported erroneously as resistant to all beta-lactams while it is actually phenotypically susceptible.
Despite the technical challenges associated with molecular detection of resistance determinants, the clinical significance of these tests was demonstrated recently by Bauer et al. (1), who used PCR for detection and differentiation of MRSA, methicillin-sensitive Staphylococcus aureus (MSSA), and CoNS strains. In this study, the GeneXpert system (Cepheid, Sunnyvale, CA) was used to identify and differentiate these strains and to determine methicillin resistance from positive blood cultures. Combining this system with an effective antimicrobial stewardship program, the investigators demonstrated a reduction in vancomycin treatment of 1.7 days, a decrease in length of stay in the intensive care unit (ICU) of 6.2 days, and an overall savings of $21,000 per patient per septic episode (1) . The potential to improve patient care and management and to provide care in a cost-sensitive manner could be substantial if similar results can be applied to a greater variety of organisms and to additional specimen sources.
DISCUSSION
The lack of progress in molecular antimicrobial susceptibility testing is attributable to several factors that include issues of regulatory compliance, significant genetic diversity of resistance determinants, the poor analytical sensitivity and specificity of assays, the need for a better understanding of the targets used, the need for multiplexing capabilities, and the problem of differential gene expression. The discussants considered two important questions related to molecular antimicrobial susceptibility testing. These included which additional targets should be considered and which technologies are the most viable for current use and future development.
Considering the assays that are commercially available, the consensus of the group was that manufacturers have addressed the targets that are readily detectible and, when present, are always expressed, but they have not advanced much beyond this stage. Commercial developers of molecular antimicrobial susceptibility assays have focused primarily on Gram-positive pathogens while forgoing the more complex issues inherent to pathogenic Gram-negative bacteria. Gram-positive targets discussed included MRSA, the vanA and vanB genes, and M. tuberculosis rifampin resistance. While each of these assays has significantly impacted clinical care, over time many have been directed to preventing health care-associated infections instead of diagnosing often severe and complicated infections as a result of antibiotic-resistant bacteria in critically ill patients. While the FDA recently approved assays for direct detection of MRSA, MSSA, and CoNS from positive blood cultures and wound specimens, the discussants concluded that a more extensive approach must be taken. Assays that focus on additional Gram-positive and Gram-negative targets must be developed and submitted for FDA clearance in order to provide a more comprehensive assessment of a patient's diagnosis and outcome.
Beyond the Gram-positive molecular targets that have already been selected and used in assay development, the discussants highly recommend expanding the current selection of molecular assays for genetic markers of resistance in Gramnegative organisms. Most critical is the detection of carbapenemase resistance determinants. Several reports (10, 13) have described the use of PCR to confirm the presence of KPCs in members of the family Enterobacteriaceae following identification of resistance by phenotypic assays. In this scheme, the modified Hodge test (MHT) is replaced by PCR, eliminating the subjectivity of MHT and confirming the presence of the KPC resistance determinant. While effective, this scheme negates the benefit of decreased turnaround time afforded by PCR applied directly to the clinical specimen or an isolated bacterial colony following growth in culture. Future studies must focus on identifying targets within the carbapenemase resistance genes and developing methods to accurately screen specimens directly for resistance rather than using molecular methods to confirm phenotypic tests. Similarly, metallo-beta-VOL. 49, NO. 9 SUPPL., 2011 ANTIMICROBIAL SUSCEPTIBILITY TESTING S21
on November 12, 2017 by guest http://jcm.asm.org/ lactamase resistance determinants must be identified early so that appropriate precautions can be taken to isolate patients and treat them most effectively. While detection of carbapenem resistance determinants is a challenge, the number of resistance determinants is manageable. Multiplex assays could be developed to screen for the few most prevalent resistance mechanism (e.g., NDM-1, bla IMP , bla VIM , and bla OXA ) among all Gram-negative isolates. To avoid erroneous results, detection of resistance determinants could be based on organism identification. For example, if Pseudomonas aeruginosa was detected, the assay would be designed to screen only for bla IMP and bla VIM , while avoiding potential false-positive results for KPC. Current multiplexing technologies could support such a panel; however, differentiating carriage from actual resistance would remain an unresolved obstacle.
A second example pertains to ESBL and AmpC resistance determinants present in Enterobacteriaceae. These Gram-negative bacteria are often found to have low MICs for many beta-lactams by phenotypic resistance screening, but patients frequently fail therapy with these agents because the antibiotics are hydrolyzed by enzymes encoded by these resistance genes. In this circumstance, the enzymes are expressed at high levels only when induced by an environmental stimulus. In this example, molecular detection of the resistance determinants is a better predictor of treatment failure than using MIC data generated from phenotypic assays. However, these resistance determinants can also be encoded chromosomally and be noninducible, which negates the risk of treatment failure. In these cases, detection of the resistance gene(s) would result in entire classes of compounds being eliminated as treatment options, potentially causing a patient to be overtreated. A second challenge to detecting ESBL and AmpC resistance determinants is the limitation of current detection technologies. To date, there have been more than 200 unique ESBLs described, and more continue to be identified. Direct detection of each of these resistance determinants requires technology with efficient multiplexing capabilities well beyond that of current PCR platforms and will most likely be based on microarrays, metabolite detection assays, or direct sequencing. Molecular approaches offer the distinct possibility of rapid and direct detection of resistance determinants from clinical material, obviating the need to recover the pathogen in culture prior to testing for the resistance factor and, in turn, significantly shortening the time to reporting of results. The key to broad implementation of these technologies will be to demonstrate that developed assays have high negative predictive values and are adequately sensitive to detect low levels of gene expression.
The second issue considered by the discussants was to determine which technologies are the most viable for current use and future development for detection of resistance. The key to implementing next-generation molecular antimicrobial susceptibility testing will be the speed with which results can be obtained and reported. If, as previously stated, the results of phenotypic susceptibility tests have little to no clinical predictive value for infections that would respond to a short course of therapy, molecular susceptibility tests must be performed in significantly less time than that required for current phenotypic methods and must also include the detection of resistance determinants for the most useful antimicrobial agents. For urinary tract infections, for instance, in order to be of significant value, testing systems must be designed to rapidly detect the relevant pathogen, determine its clinical significance, and provide results that support appropriate therapeutic options within hours of specimen collection. This requires a technology capable of multiplexing a large array of targets without being too sensitive and detecting contaminating organisms. It may also require that the technology actually be able to quantify the bacterial load or burden in order to predict the likelihood that a given organism is a suspected pathogen or a contaminant.
Detection of resistance determinants requires technologies capable of high-throughput multiplexing. Real-time PCR has revolutionized clinical molecular diagnostics, allowing amplification and detection of targets in a closed system within 45 min to 2 h. The current impediment to this technology is the limited number of unique fluorophores that can be used for simultaneous detection of multiple targets, as most systems are currently limited to 6 or fewer detection channels. In order to build assays that can simultaneously identify and/or quantify pathogens, if necessary, and efficiently detect multiple common resistance determinants, molecular platforms may need to be capable of detecting hundreds of targets. Currently, liquid-and solid-phase microarrays may best fill this need. Liquid arrays such as the Luminex XTAG technology (Luminex, Austin, TX) use microspheres labeled with red dye to simultaneously detect up to 100 targets in a single reaction tube. Simultaneous detection of 100 targets would address the diverse common resistance determinants in the family Enterobacteriaceae; however, in its current form, the XTAG technology is labor-and time-intensive and requires a PCR to link the microspheres to an amplicon. This increases the turnaround of the assay to 6 to 8 h, with several hands-on steps, resulting in a test that would not be capable of providing timely information about antimicrobial resistance that would be significant for effective treatment of urinary tract infections. Luminex currently offers a commercial respiratory virus assay and is developing a stool pathogen panel but has not developed any assays for antimicrobial resistance targets. A second liquid array technology, BeadExpress (Illumina, San Diego, CA), uses holographic beads to label targets. The BeadExpress system boasts an impressive 300 targets that can be detected simultaneously, but it has not been tested in a clinical laboratory or with antimicrobial resistance targets.
Solid arrays have been used in research laboratories for more than a decade, but transition of this technology to the clinical laboratory has been slow. Nanosphere Inc. (Northbrook, IL) has developed an array that can simultaneously identify Staphylococcus spp., S. aureus, Streptococcus spp., the Streptococcus anginosus group, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, and Micrococcus spp., in addition to detecting mecA, vanA, and vanB directly from positive blood cultures. The system requires Ͻ1 ml of a positive blood culture and will identify the agents listed above and determine the presence of methicillin and vancomycin resistance markers within 2.5 h. The system involves little hands-on time and can be performed in a random-access format, allowing specimens to be run continuously as they arrive in the laboratory. While this is certainly a positive step forward, identification of additional targets, such as Grampositive rods and macrolide resistance markers, would be ben-eficial. Providing a panel to include these organisms and resistance determinants is theoretically possible, as this array system is capable of detecting several thousand targets on a single slide. Other solid array systems, such as the GeneChip (Affymetrix, Santa Clara, CA) and BioFilmChip (Autogenomics, Vista, CA) systems, also offer highly multiplexed detection but have not been evaluated for suitability for molecular antimicrobial susceptibility testing.
The discussants concluded that current multiplexing technologies offer high-throughput solutions for molecular susceptibility testing. However, many of the technologies require multiple manipulations and may not provide optimal turnaround times. These assays also do not overcome the challenge of detecting carriage versus expression of resistance determinants.
A final technology discussed during the symposium was a significant departure from traditional molecular techniques. Instead of identifying DNA or RNA segments that encode resistance determinants, the optimal assay would involve proteomics and the identification of the proteins responsible for resistance to various antimicrobials. Significant advances have been made in mass spectrometry, with more than 200 reports describing matrix-associated laser desorption ionization-time of flight (MALDI-TOF) identification of bacteria. However, direct detection of resistance determinants has remained elusive because many proteins involved in drug resistance, such as the beta-lactamases, are frequently not expressed at high levels compared to other bacterial proteins. This makes it nearly impossible to identify and differentiate the beta-lactamase proteins from the rest of the protein spectrum. A solution to this issue may involve using a MALDI-TOF mass spectrometer to detect the metabolites produced as a result of the beta-lactamase hydrolysis reaction rather than the beta-lactamase itself. When a beta-lactamase attaches to a beta-lactam antibiotic, it increases the molecular mass of the beta lactam by several Daltons. When the hydrolysis reaction is complete, the mass of the hydrolyzed antibiotic is 44 Da lower than that at the beginning of the reaction. As shown in Fig. 1 , this change in mass as a result of hydrolysis can be detected using a mass spectrometer. The protocol would involve incubating a bacterial isolate of interest in the presence of a beta-lactam antimicrobial for 1 to 3 h and then assaying the culture supernatant for the antimicrobial hydrolysis product at the completion of the reaction (Fig. 2) . This method has significant potential but may not replace all antimicrobial susceptibility testing due to the multiple manipulations required and the variability of antimicrobial targets (targets that do not involve direct metabolism of the antibacterial cannot be detected using this method).
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